GBI Research, June 2011, Pages: 95
for the Prescription and Lifestyle Drugs 25
3.5.3 Proliferation of Online Drug Sale Channels 25
3.5.4 Price Controls by the Government 26
3.5.5 Availability of Sophisticated Tools for Counterfeiting 26
3
Business Insights, Sep 2009, Pages: 148
following legislation allowing drugs to be imported into the US from Canada. However, counterfeitdrugs have been shown to be increasingly introduced into the global supply chain, which threatens patient
Markets and Markets, Feb 2011, Pages +: 251
expanded in developed nations such as the U.S. and Europe. Counterfeit medicines in particular are on the increase. The most commonly counterfeiteddrugs in developed countries are the so-called ‘lifestyle
GBI Research, Feb 2010, Pages: 89
Industry’s Pressing Need to Regain Lost Reputation and Revenues Due to CounterfeitDrugs Will Drive the Growth of the RFID Market
The authors find that there is a growing need for the pharmaceutical
Decision Resources, Inc., Dec 2009, Pages: 25
healthcare in the Soviet era; public healthcare reform in the post-Soviet era; private healthcare.
- Regulatory environment: drug licensing; intellectual property rights; counterfeiting.
- Pharmaceutical
FirstWord Publishing, June 2010, Pages: 46
growth rates by 2013.
While some leading companies have already established their foothold in those regions with the standard approach of offering low-volume innovative drugs to the emerging middle class
RNCOS E-Services Private Limited, March 2011, Pages: 60
of both revenue and prescriptions. The US generic drugs market has been growing at a fast pace on the back of factors, such as demand for cost-effective medications, patent expiration of blockbuster drugs
Markets and Markets, April 2010, Pages: 118
4.1 Brazil Diabetes Drugs Market
4.1.1 Drivers & Restraints
4.1.1.1 Initiatives By The Brazilian Government
4.1.1.2 Patent Expiry Of Key Branded Drugs
4.1.1.3 Counterfeiting Of Drugs
4
John Wiley and Sons Ltd, Aug 2011, Pages: 426
The scourge of counterfeitdrugs poses an ever-increasing threat to the global healthcare system. The problem is not limited to internet pharmacies or developing countries but has the potential
Frost & Sullivan, Dec 2006, Pages: 32
chains.
The absence of integration across the supply chain and the inability to track products at each stage has given rise to counterfeiting of drug products. About 5 to 8 per cent of prescriptiondrugs
Global Industry Analysts, Inc., Aug 2011, Pages: 228
, and low priced drugs, particularly to those residing in remote locations and those who are homebound either due to a disease or aging. ePharmacies are playing a significant role in the prescriptiondrugs
Business Monitor International, March 2010, Pages: 73
-capita spending on medicines at US$123.4. Prescriptiondrug spending was US$460mn, or 89.7% of the total market. Prescription medicines expenditure is forecast to increase as a proportion of the total
GBI Research, Feb 2010, Pages: 107
“Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting.” provides key data, information and analysis of the major trends and issues affecting the drug
Taiyou Research, Nov 2011, Pages: 240
of the market for the OTC market, market for prescriptiondrugs, and the generics market. Healthcare reforms that have recently been changing the industry landscape are analyzed. Unstable and fragment distribution channels
Business Monitor International, Nov 2010, Pages: 96
market. They expect combined sales of prescriptiondrugs and over-the-counter (OTC) medicines to increase from NGN84.26bn (US$564mn) in 2009 to NGN94.25bn (US$633mn) in 2010 – an 11.9% increase in local currency terms
Datamonitor, Dec 2010, Pages: 225
France – Prescription pharmaceutical sales analysis
France – Drug expiry analysis
France – Pharmaceutical Industry Infrastructure analysis
Related reports
Upcoming related reports
2
Business Monitor International, Jan 2011, Pages: 108
Of Counterfeit Medicines In The UK
- Pricing Regime
Table: Bilateral Comparisons For Ex-Manufacturer Prices*
- Generic Drug Prices
- OTC Prices
- Reimbursement Regime
Industry Developments
- Epidemiology
